1. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Sauter, C.S.; Matasar, M.J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M.L.; Portlock, C.S.; Straus, D.J.; Zelenetz, A.D.; McCall, S.S.; Miller, S.T.; Courtien, A.I.; Younes, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Batlevi, C.L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Moskowitz, A.J.; Moskowitz, C.H.; Noy, A.; Palomba, M.L.; Portlock, C.; Straus, D.; Boccomini, C.; Tucci, A.; Zelenetz, A.D.; Seshan, V.E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY. (12th June 2019) Authors: Morschhauser, F.; Flinn, I.W.; Gasiorowski, R.; Illés, Á.; Feugier, P.; Greil, R.; Johnson, N.A.; Larouche, J.; Lugtenburg, P.J.; Patti, C.; Salles, G.; Trněný, M.; de Vos, S.; Mir, F.; Kornacker, M.; Punnoose, E.A.; Samineni, D.; Szafer‐Glusman, E.; Petrich, A.; Sinha, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS. (12th June 2019) Authors: Rajeeve, S.; Bobillo, S.V.; Zelenetz, A.D.; Straus, D.J.; Palomba, M.L.; Noy, A.; Horwitz, S.M.; Moskowitz, A.J.; Hamlin, P.A.; Matasar, M.J.; Kumar, A.; Batlevi, C.L.; von Keudell, G.; Yahalom, J.; Dogan, A.; Drill, E.; Younes, A.; Joffe, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 264 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES. (June 2017) Authors: Ghalie, R.G.; Pagel, J.M.; Soumerai, J.; Iasonos, A.; Patel, K.; Moreno, O.; Butler, T.; Zelenetz, A.D. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. (12th June 2019) Authors: Mato, A.R.; Svoboda, J.; Luning Prak, E.T.; Schuster, S.J.; Tsao, P.Y.; Dorsey, C.; Sarmasti, L.M.; Becker, P.S.; Brander, D.M.; Nasta, S.; Landsburg, D.J.; King, C.M.; Morrigan, B.; Elwell, J.; Kennard, K.; Roeker, L.; Zelenetz, A.D.; Purdom, M.; Paskalis, D.; Sportelli, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL). (12th June 2019) Authors: Zelenetz, A.D.; Jagadeesh, D.; Kenkre, V.P.; Reddy, N.M.; Stathis, A.; Salman, H.S.; Asch, A.S.; Soumerai, J.; Jhangiani, H.S.; Iasonos, A.; Patel, K.; Carter, J.; LLorin‐Sangalang, J.; Pagel, J.M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. (June 2017) Authors: Soumerai, J.D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K.S.; Palomba, M.; Gerecitano, J.F.; Noy, A.; Hamlin, P.; Moskowitz, C.H.; Copeland, A.R.; Matasar, M.J.; Drullinsky, P.R.; Hamilton, A.; Horwitz, S.M.; Intlekofer, A.M.; Kumar, A.; Moskowitz, A.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗